Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.60 |
| ▸ | ARG2 | P78540 | 1/20 | 0.60 |
| ▸ | NOS2 | P35228 | 5/20 | 0.58 |
| ▸ | NOS1 | P29475 | 3/20 | 0.58 |
| ▸ | NOS3 | P29474 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | BHMT | Q93088 | 5/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106818 | 1.00 | ARG1 (0.60) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL17852468 | 0.92 | NOS2 (0.60) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL25678741 | 0.87 | ARG1 (0.46) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL17361240 | 0.86 | ARG1 (0.69) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL17361239 | 0.86 | ARG1 (0.69) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL1867971 | 0.84 | BHMT (0.62) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL1867969 | 0.84 | BHMT (0.62) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL16439028 | 0.83 | ALOX15 (0.52) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL27552293 | 0.82 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL2781165 | 0.82 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-10800816-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2020-10-13 | — | — | US | disclosed |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-09 | — | — | US | disclosed |
| US-10201586-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2019-02-12 | — | — | US | disclosed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | disclosed |
| US-9873720-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2018-01-23 | — | — | US | disclosed |
| US-9873720-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2018-01-23 | — | — | US | disclosed |
| US-20170174727-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2017-06-22 | — | — | US | disclosed |
| WO-2013141965-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20130252896-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER HEALTHCARE SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130252896-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER HEALTHCARE SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-8450275-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450275-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011115712-A2 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20090022862-A1 | Method to limit acrylamide in heated foods | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2006017526-A2 | METHOD TO LIMIT ACRYLAMIDE IN HEATED FOODS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | ARG1 1935/4885ARG2 3701/4885NOS2 3014/4885 |
| US-20170174727-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | ARG1 1900/4885ARG2 3706/4885NOS2 3173/4885 |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | ARG1 1900/4885ARG2 3706/4885NOS2 3173/4885 |
| US-20130252896-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | ARG1 1900/4885ARG2 3706/4885NOS2 3173/4885 |
| US-10201586-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | ARG1 1987/4885ARG2 3703/4885NOS2 3085/4885 |
| US-11793855-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | ARG1 1987/4885ARG2 3703/4885NOS2 3085/4885 |
| US-10800816-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F13B | ARG1 1900/4885ARG2 3706/4885NOS2 3173/4885 |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | ARG1 1987/4885ARG2 3703/4885NOS2 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.